TSX:ONC - Spark Newswire

1 minute read

Cantor Fitzgerald Initiates Coverage On Oncolytics Biotech with Overweight Rating, Announces Price Target of C$9

Today, 12:08 PM

Cantor Fitzgerald analyst Louise Chen initiates coverage on Oncolytics Biotech (TSX:ONC) with a Overweight rating and announces Price Target of C$9.

TSX:ONC

3 minute read

Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS

By Benzinga Newsdesk

Today, 12:08 PM

Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /CNW/ -- Oncolytics

ONCY

2 minute read

Oncolytics Biotech Receives FDA Fast Track Designation For The Treatment Of Advanced/Metastatic Pancreatic Cancer

By Benzinga Newsdesk

Today, 12:08 PM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1

ONCY

2 minute read

Oncolytics Biotech Partner Adlai Nortye Advances To The Second Dose Escalation Cohort Of The Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment In Breast Cancer

By Benzinga Newsdesk

Today, 12:08 PM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety,

ONCY

2 minute read

Oncolytics Biotech Provides Enrollment Update On Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial At The 2022 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

By Benzinga Newsdesk

Today, 12:08 PM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers

ONCY

2 minute read

News

Oncolytics Biotech Announces Preclinical Data Demonstrating The Synergistic Immunotherapeutic Effects Of Pelareorep Combined With Radiotherapy

By Benzinga Newsdesk

Today, 12:08 PM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data

ONCY

1 minute read

Oncolytics Biotech Q2 EPS $(0.13) Up From $(0.17) YoY

By Benzinga Newsdesk

Today, 12:08 PM

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.13) per share. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.

ONCY

Feed Symbols: TSX:ONC

Cantor Fitzgerald Initiates Coverage On Oncolytics Biotech with Overweight Rating, Announces Price Target of C$9

Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS

Oncolytics Biotech Receives FDA Fast Track Designation For The Treatment Of Advanced/Metastatic Pancreatic Cancer

Oncolytics Biotech Partner Adlai Nortye Advances To The Second Dose Escalation Cohort Of The Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment In Breast Cancer

Oncolytics Biotech Provides Enrollment Update On Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial At The 2022 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Oncolytics Biotech Announces Preclinical Data Demonstrating The Synergistic Immunotherapeutic Effects Of Pelareorep Combined With Radiotherapy

Oncolytics Biotech Q2 EPS $(0.13) Up From $(0.17) YoY